StemRIM

Tokyo Stock Exchange 4599.T

StemRIM Price to Book Ratio (P/B) on January 31, 2025: 2.13

StemRIM Price to Book Ratio (P/B) is 2.13 on January 31, 2025, a -32.22% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

StemRIM 52-week high Price to Book Ratio (P/B) is 3.33 on August 27, 2024, which is 56.59% above the current Price to Book Ratio (P/B).
StemRIM 52-week low Price to Book Ratio (P/B) is 1.90 on December 26, 2024, which is -10.50% below the current Price to Book Ratio (P/B).
StemRIM average Price to Book Ratio (P/B) for the last 52 weeks is 2.56.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Tokyo Stock Exchange: 4599.T

StemRIM

CEO	Mr. Masatsune Okajima
IPO Date	Aug. 9, 2019
Location	Japan
Headquarters	Saito Bio-Incubator
Employees	45
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. It develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy; PJ2, a regeneration-inducing medicine novel peptides A and B; PJ3, a biologic regeneration-inducing protein; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.

Key trends

Past 5 years